Introduction
============

Nasopharyngeal carcinoma (NPC) is the most prevalent malignancy in southern China and Southeast Asia. In total, \~129,000 new cases are reported annually worldwide, with \>70% reported in South China and Southeast Asia ([@b1-ol-0-0-11412]). Its pathogenesis is associated with three primary etiological factors; Epstein-Barr virus infection, genetic susceptibility and environmental condition ([@b2-ol-0-0-11412]). However, the pathophysiological mechanism underlying NPC progression is yet to be elucidated.

Previous studies have predominantly focused on the function of specific genes expressed in NPC instead of the molecular pathogenesis of the disease ([@b1-ol-0-0-11412],[@b2-ol-0-0-11412]). Notably, \>98% of human genes are non-protein coding, and the expression of these genes generates non-coding RNAs (ncRNAs) ([@b3-ol-0-0-11412]). There are multiple families of ncRNA, including ribosomal (r), short interfering (si), micro (mi), circular (circ) and long non-coding (lnc)RNA ([@b4-ol-0-0-11412]--[@b6-ol-0-0-11412]). The latter refers to ncRNAs \>200 nucleotides in length ([@b4-ol-0-0-11412],[@b5-ol-0-0-11412]). Previous studies have reported that lncRNAs are important regulators of numerous biological processes, including tumor progression ([@b7-ol-0-0-11412],[@b8-ol-0-0-11412]). miRNAs are a class of small ncRNAs of \~22 nucleotides, which serve as key regulators of multiple disease-associated processes ([@b9-ol-0-0-11412]). Unlike linear RNA, circRNAs exhibit a covalently closed continuous loop, and serve as an miRNA sponge to regulate transcription ([@b10-ol-0-0-11412]). A number of studies have indicated that ncRNAs play important roles in transcriptional regulation by forming regulatory networks and subsequently interacting with their respective target genes ([@b4-ol-0-0-11412]--[@b7-ol-0-0-11412]).

lncRNAs and miRNAs have become increasingly associated with the progression of NPC ([@b11-ol-0-0-11412]); however, the majority of studies have solely focused on the role of single or small groups of these molecules. Ma *et al* ([@b12-ol-0-0-11412]) reported that lncRNA HOX transcript antisense RNA contributes towards the tumorigenesis of NPC via the upregulation of fatty acid synthase. Moreover, Zhang *et al* ([@b13-ol-0-0-11412]) discovered that miRNA-200c acts as an oncogene in NPC, by regulating the phosphatase and tensin homolog genes. To the best of our knowledge, a limited number of studies to date have investigated the association between circRNA expression and NPC, and no data are currently available concerning circRNAs and their target genes in NPC. Shuai *et al* ([@b14-ol-0-0-11412]) indicated that circRNA_0000285 may be used as a novel biomarker for NPC radiosensitivity. As the initiation and progression of different types of tumor is a multi-gene, multi-step process, research is typically focused on gene regulatory networks at a genome-wide level.

The purpose of the present study was to comprehensively analyze the expression profiles of lncRNAs, circRNAs and mRNAs in NPC, and their inter-regulatory molecular mechanisms. It was also aimed to identify the target genes of differentially expressed (DE) lncRNAs and circRNAs, and the DE genes (DEGs) within key signaling pathways influencing NPC progression, in order to elucidate the regulatory network in NPC. First, the present study compared the transcriptome profiling of lncRNAs, circRNAs and mRNAs between NPC and chronic nasopharyngitis (CNP) tissues, using microarray technology at the whole genome level. Subsequently, integrated bioinformatics analysis was performed on the three microarray datasets. The results of the present study may help to clarify the associations between lncRNAs, circRNAs and miRNAs (and their target genes), and elucidate the notable regulatory networks involved in the molecular pathogenesis of NPC.

Materials and methods
=====================

### Specimens

A total of 42 human nasopharyngeal tissue samples were collected from 42 patients (30 men and 12 women) during nasopharyngeal biopsy between August 2013 and October 2014, at Zhongshan Hospital (Ximen, China). The tissue samples included 21 cases of primary NPC and 21 cases of CNP from patients suspected of having cancer. All specimens were confirmed by histopathological examination. Patients did not receive chemoradiotherapy and biotherapy prior to biopsy. The 21 patients with primary NPC comprised 15 men and six women (age range, 20--69 years; median, 45.5 years), and the 21 patients with CNP comprised 16 men and five women (age range, 21--60 years; median, 43.2 years).

All tissues were immediately stored at −80°C following biopsy, prior to subsequent RNA extraction. Tumor tissues were isolated via micro-dissection and specimens containing \>70% tumor cells were further analyzed. In total, six pairs of NPC and CNP specimens among the 42 collected tissues were selected for lncRNA, mRNA and circRNA expression microarray, while all 42 specimens were used for reverse transcription-quantitative (RT-q)PCR. These specimens were used to evaluate differences in the expression levels between NPC and CNP tissues. The present study was approved by the Medical Ethics Committee of Zhongshan Hospital, Xiamen University (Fujian, China) and written informed consent was obtained from all patients prior to the study start.

### RNA extraction and quality control

Total RNA was extracted from each tissue sample using TRIzol^®^ reagent (Invitrogen; Thermo Fisher Scientific, Inc.) and purified using the RNeasy Mini kit (Qiagen GmbH), according to the manufacturers\' protocol. The quantity and quality of the RNA were determined using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc.) and the RNA integrity was assessed via electrophoresis on a denaturing agarose gel.

### RNA labeling, lncRNA and mRNA microarray

Sample labeling and microarray hybridization were performed using a modified version of the Agilent One-Color Microarray-Based Gene Expression Analysis protocol (Agilent Technologies, Inc.). The rRNA was removed from the total RNA sample using the Ribo-Zero™ rRNA Removal kit (Epicentre; Illumina, Inc.) and mRNA was purified using the mRNA-ONLY™ Eukaryotic mRNA Isolation kit (Epicentre; Illumina, Inc.). Subsequently, each sample was amplified and transcribed into fluorescent cRNA along the entire length of the transcripts, using a random priming method. The labeled cRNAs were purified using the RNeasy Mini kit (Qiagen GmbH), and the concentration and specific activity of the labeled cRNAs \[pmol cyanine (Cy)3/µg cRNA\] were measured using NanoDrop ND-1000 (NanoDrop Technologies; Thermo Fisher Scientific, Inc.). A total of 0.6 µg of each labeled cRNA was fragmented via the addition of 5 µl 10X blocking agent and 1 µl 25X fragmentation buffer. The mixture was heated at 60°C for 30 min, and 25 µl 2X GEx hybridization buffer (Agilent Technologies, Inc.) was added to dilute the labeled cRNA. A total of 40 µl hybridization solution was dispensed into a gasket slide and placed into the Human LncRNA Array (version 3.0; 8×60 K; Arraystar, Inc.), which contained 30,586 lncRNAs and 26,109 mRNAs. The slides were incubated for 17 h at 65°C in an Agilent Microarray hybridization oven. The hybridized arrays were washed with Gene Expression Wash Buffer (Agilent Technologies, Inc.) and subsequently fixed with 3.7% paraformaldehyde for 15 min at room temperature prior to being scanned using the Agilent DNA Microarray Scanner System (G2505C; Agilent Technologies, Inc.).

Agilent Feature Extraction software (version 11.0.1.1; Agilent Technologies, Inc.) was used to analyze the acquired array images. Quantile normalization and subsequent data processing were performed using the GeneSpring GX software package (version 11.5.1; Agilent Technologies, Inc.). Following quantile normalization of the raw data, lncRNAs and mRNAs that were flagged as Present or Marginal ('All Targets Value'), in ≥6 out of 12 samples, were selected for further analyses. Significantly DE lncRNAs and mRNAs (fold-change ≥2.0; P≤0.05) between the two groups were identified via volcano plot filtering. Hierarchical clustering was performed using the Agilent GeneSpring GX software (version 11.5.1; Agilent Technologies, Inc.). Gene Ontology (GO; <http://geneontology.org>) and Kyoto Encyclopedia of Genes and Genomes (KEGG; <http://www.genome.jp/kegg>) pathway analyses were performed using the standard enrichment computation method for DE mRNAs. GO analysis was performed in order to characterize genes and gene products in terms of cellular component, molecular function and biological process. KEGG pathway analysis was performed to identify the signaling pathways in which DE mRNAs underwent significant enrichment, and thus predict the underlying biological functions of the DEGs. P\<0.05 and the false discovery rate denoted the significance of the GO term enrichment and the biological pathways. The computational data analysis was performed by Kangchen BioTech Co., Ltd.

### RNA labeling and circRNA microarray

Sample labeling and Arraystar Human circRNA Array hybridization (Arraystar, Inc.) were performed according to the manufacturer\'s protocol. Briefly, circRNAs were treated with RNase R (Epicentre; Illumina, Inc.) to remove the linear RNA. Each sample was subsequently amplified and transcribed into fluorescent cRNA using the Arraystar Super RNA Labeling kit (Arraystar, Inc.) and a random priming method. The labeled cRNAs were purified using the RNeasy Mini kit (Qiagen GmbH) and the concentration and specific activity of the labeled cRNAs (pmol Cy3/µg cRNA) was determined using NanoDrop ND-1000 (NanoDrop Technologies; Thermo Fisher Scientific, Inc.). A total of 1 µg of each labeled cRNA was fragmented using 5 µl 10X blocking agent and 1 µl 25X fragmentation buffer. The sample was heated at 60°C for 30 min, and 25 µl 2X hybridization buffer (Agilent Technologies, Inc.) was added to dilute the labeled cRNAs. A total of 50 µl of hybridization solution was dispensed into a gasket slide and assembled into the Arraystar Human CircRNA Microarray slide (Arraystar, Inc.). The slides were incubated for 17 h at 65°C in an Agilent hybridization oven. The hybridized arrays were washed with Gene Expression Wash Buffer (Agilent Technologies, Inc.) and subsequently fixed in 3.7% paraformaldehyde for 15 min at room temperature, prior to being scanned using the Agilent Microarray Scanner System (Agilent Technologies, Inc.).

The scanned images were imported into Agilent Feature Extraction software (version 11.0.1.1; Agilent Technologies, Inc.) for raw data extraction. Quantile normalization of the raw data and subsequent data processing were performed using the R software package (version 3.28.0; <http://bioconductor.org/packages/edgeR>). Low-intensity filtering was performed and circRNAs that were flagged as Present or Marginal ('All Targets Value') in ≥6 out of 12 samples were retained for further analyses. The fold-change between the groups for each circRNA was computed to allow for comparisons between two groups of profile differences (such as cancer vs. inflammation). circRNAs with a fold-change ≥1.5 and P≤0.05 were selected as significantly DE. The analysis outputs were filtered and the DE circRNAs were ranked according to their fold-change and P-value using Microsoft Excel\'s Data/Sort & Filter functionalities (Microsoft Corporation). The computational data analysis was performed by Kangchen BioTech Co., Ltd.

### RT-qPCR validation

Randomly selected DE lncRNAs, mRNAs and circRNAs were evaluated using RT-qPCR. The specific primer sequences for 12 lncRNAs, eight mRNAs and four circRNAs were designed using Primer (version 5.0; Premier Biosoft, Inc.) and are presented in [Table SI](#SD1-ol-0-0-11412){ref-type="supplementary-material"}. The total RNA (1.5 µg) was reverse transcribed into cDNA using the PrimeScript™ RT Reagent kit (Takara Bio, Inc.), according to the manufacturer\'s protocol. qPCR was performed on a total reaction volume of 10 µl, comprised of 5 µl 2X Master Mix (Arraystar, Inc.), 0.5 µl each of the PCR forward and reverse primers (10 µM), 2 µl DNA and 2 µl double-distilled water. The following thermocycling conditions were used for RT-qPCR: An initial denaturation step of 10 min at 95°C, followed by 40 cycles of 95°C for 10 sec and 60°C for 1 min. All experiments were performed in triplicate. For RT-qPCR validation analysis, all 42 samples were normalized to GAPDH. The fold-change in expression was calculated using the 2^−ΔΔCq^ method ([@b15-ol-0-0-11412]).

### Identification of the nearby coding genes of DE lncRNAs

A nearby coding gene is defined as a coding transcript \<300 kb between the DE lncRNA and the neighboring coding mRNA. In the present study, genomic coordinate analysis of DE lncRNAs was performed alongside computational analysis of lncRNA and mRNA microarray data. The NPC-associated DE lncRNAs and their neighboring coding genes were annotated, and genomic coordinates of the lncRNAs, and the association between an lncRNA and its nearby coding gene were also detailed. Additionally, nearby coding genes of DE lncRNAs in NPC were obtained following lncRNA classification, subgroup analysis and genomic coordinate determination.

### Predictive analysis of potential targets of DE circRNAs

Overlap analysis was performed via three steps. First, the circRNA-miRNA interaction was predicted with Arraystar\'s proprietary miRNA target prediction software (version 1.0) using datasets retrieved from the TargetScan and miRanda databases, and the DE circRNAs within all the comparisons were annotated in detail using the circRNA-miRNA interaction information. A total of five target miRNAs for each DE circRNA were subsequently identified according to the number of conservative miRNA binding sites. Subsequently, the candidate target mRNAs for the selected target miRNAs of DE circRNAs were analyzed using Overlap software (version 1.0; Kangchen BioTech Co., Ltd.), based on three miRNA databases (miRanda, miRDB and TargetScan). The intersection of the mRNAs between the aforementioned candidate mRNAs, and the mRNAs in the lncRNA and mRNA microarray data, was determined using Venny software (version 2.1; <http://bioinfogp.cnb.csic.es/tools/venny/index.html>).

Following the determination of DE circRNAs and their corresponding target genes, the circRNA-miRNA-mRNA regulatory network was constructed and visualized using Cytoscape software (version 3.7.1; <http://www.cytoscape.org>).

### Statistical analysis

The differences in lncRNA, circRNA and mRNA expression levels between NPC and CNP tissues (from the microarray and RT-q-PCR data) were analyzed using the paired Student\'s t-test, according to their fold-change. Fisher\'s exact test was used for GO and pathway analyses. P\<0.05 was considered to indicate a statistically significant difference. For the microarray analysis, the false discovery rate was calculated to correct the P-value.

Results
=======

### Profiles of DE lncRNAs and mRNAs

Among all the lncRNA and mRNA probes in the microarray, 2.80% (856/30,586) lncRNAs (425 upregulated and 431 downregulated) and 2.94% (767/26,109) mRNAs (426 upregulated and 341 downregulated) were significantly DE between the two groups ([Tables SII](#SD2-ol-0-0-11412){ref-type="supplementary-material"} and [SIII](#SD3-ol-0-0-11412){ref-type="supplementary-material"}). The top 20 most significantly DE lncRNAs consisted of more upregulated lncRNAs compared with downregulated lncRNAs (ratio, 16:4). Furthermore, uc004ebm.1 (fold-change, 38.478134) was the most significantly upregulated lncRNA, while ENST00000572818 was the most significantly downregulated lncRNA (fold-change, 12.04174). Of the 20 most significantly DE mRNAs; the number of upregulated and downregulated mRNAs were equal (ratio, 10:10). Furthermore, SPRR2E (fold-change, 63.81733) was the most significantly downregulated mRNA, while PCDH10 (fold-change, 18.465176) was the most significantly upregulated mRNA. Differences in mRNA expression between NPC and CNP tissues are presented using a volcano plot, scatter plot and clustering heat-map ([Fig. 1A-C](#f1-ol-0-0-11412){ref-type="fig"}, respectively). In addition, pathway analysis revealed that 31 significantly enriched signaling pathways (18 upregulated and 13 downregulated) corresponded to DE mRNAs in this microarray ([Tables I](#tI-ol-0-0-11412){ref-type="table"}, [II](#tII-ol-0-0-11412){ref-type="table"}, [SIV](#SD4-ol-0-0-11412){ref-type="supplementary-material"} and [SV](#SD5-ol-0-0-11412){ref-type="supplementary-material"}).

### Profiles of DE circRNAs

In the circRNA microarray, 0.96% of all probes (31 circRNAs, 18 upregulated and 13 downregulated) were significantly DE between the NPC and CNP samples ([Tables III](#tIII-ol-0-0-11412){ref-type="table"} and [SVI](#SD6-ol-0-0-11412){ref-type="supplementary-material"}). These comprised two circRNAs (upregulated); hsa_circRNA_100160 (circRNA identifier) and hsa_circRNA_100989, with \>6-fold-change differences in expression. The variation of circRNAs between NPC and CNP tissues is presented in a volcano plot, scatter plot and clustering heat map ([Fig. 2A-C](#f2-ol-0-0-11412){ref-type="fig"}, respectively).

### Validation of selected DE lncRNAs, mRNAs and circRNAs using RT-qPCR

Of the 12 selected DE lncRNAs (NR_027358, ENST00000566575, ENST00000560280, ENST00000411815, ENST00000565929, ENST00000457799, ENST00000514571, ENST00000440518, uc010zye.1, ENST00000443373, ENST00000513638 and ENST00000429469), only ENST00000560280 exhibited significantly opposing microarray expression patterns, which was compared with those resulting from RT-q-PCR analysis. Changes in the expression levels of the other 11 lncRNAs were also verified by RT-q-PCR ([Fig. 3A](#f3-ol-0-0-11412){ref-type="fig"}). Of the 8 selected DE mRNAs (SHISA8, XAF1, RORA, MEF2C, TXLNB, MCM2, STAT1 and caspase 3), the expression levels of all except MCM2 exhibited the same trends of up- and downregulation as the microarray data, which indicated a significant difference between NPC and CNP tissues, following RT-qPCR ([Fig. 3B](#f3-ol-0-0-11412){ref-type="fig"}). The changes in expression of the four selected DE circRNAs (hsa_circRNA_104204, hsa_circRNA_101252, hsa_circRNA_100160 and hsa_circRNA_001430) were consistent with the results of microarray analysis ([Fig. 3C](#f3-ol-0-0-11412){ref-type="fig"}).

### Prediction of potential targets of DE lncRNAs

Following bioinformatics and genomic coordinate analyses, the NPC-associated nearby coding genes of DE lncRNAs were listed in the relevant tables ([Tables IV](#tIV-ol-0-0-11412){ref-type="table"}, [V](#tV-ol-0-0-11412){ref-type="table"}, [SII](#SD1-ol-0-0-11412){ref-type="supplementary-material"}, [SVII](#SD7-ol-0-0-11412){ref-type="supplementary-material"} and [SVIII](#SD8-ol-0-0-11412){ref-type="supplementary-material"}), including their association and corresponding gene accession number, gene name, protein name, gene strand, gene start location and gene end location. In summary, 420 NPC-associated nearby coding genes, corresponding with DE lncRNAs, were accurately defined and comprised 196 upregulated and 224 downregulated genes.

### Prediction of potential targets within significant pathway

In total, 31 significantly enriched signaling pathways (18 associated with upregulated and 13 associated with downregulated genes) were obtained via pathway analysis. Among the 31 signaling pathways corresponding to DE mRNAs, each included a different number of DEGs associated with the pathway identifier. The most significant enrichment pathway was upregulated and included 20 targeted genes associated with 'cytokine-cytokine receptor interaction-*Homo sapiens* (human)'. The least significantly enriched pathways were downregulated and only included two target genes; the target genes, SULT2B1 and SUOX, were involved in 'Sulfur Metabolism-*Homo sapiens* (human)', while the CTSG and MME genes were identified within the 'Renin-angiotensin system-*Homo sapiens* (human)'. In summary, 221 potential target genes are closely associated with 31 key signaling pathways in NPC ([Tables I](#tI-ol-0-0-11412){ref-type="table"} and [II](#tII-ol-0-0-11412){ref-type="table"}).

### Prediction of potential target miRNAs of DE circRNAs

All DE circRNAs were annotated in detail with their respective circRNA-miRNA interaction network information ([Table SVI](#SD4-ol-0-0-11412){ref-type="supplementary-material"}). A total of five miRNA response elements for each DE circRNA were predicted from the results of the circRNA microarray ([Table III](#tIII-ol-0-0-11412){ref-type="table"}).

### Prediction of potential targets of DE circRNAs

In combination with the lncRNA, mRNA and circRNA microarray datasets, the original results of the overlap analysis were exported ([Table SIX](#SD9-ol-0-0-11412){ref-type="supplementary-material"}). Upon induction, 23 DE circRNAs (16 upregulated and 7 downregulated) and their associated target genes (37 miRNAs and 50 mRNAs) were selected. A regulatory network, including 37 circRNA-miRNA interactions and 50 miRNA-mRNA interactions, was then constructed ([Table VI](#tVI-ol-0-0-11412){ref-type="table"} and [Fig. 4](#f4-ol-0-0-11412){ref-type="fig"}), in which 14 circRNA-miRNA-mRNA regulatory modules were identified ([Fig. 5](#f5-ol-0-0-11412){ref-type="fig"}). According to the data, there is no one-to-one correspondence between circRNA and its target genes. For example, hsa_circRNA_104405 is associated with 2 target miRNAs (hsa-miR-122-5p and hsa-miR-205-5p), while hsa-miR-122 is associated with 1 target mRNA (RIMS1) and hsa-miR-205-5p is associated with 3 target mRNAs (CENPF, FRK and SCD5).

Discussion
==========

NPC is a type of head and neck cancer with a high incidence and poor overall survival rate, particularly in the endemic regions of Southeast Asia ([@b4-ol-0-0-11412]). Although a clear understanding of its etiology is yet to be determined, NPC is widely suspected to be the result of both genetic susceptibility, exposure to certain environmental factors or Epstein-Barr virus infection ([@b1-ol-0-0-11412],[@b2-ol-0-0-11412]). Genome-wide association and regulatory ncRNA studies may improve understanding of the etiological and essential molecular mechanisms underpinning NPC progression ([@b14-ol-0-0-11412],[@b16-ol-0-0-11412],[@b17-ol-0-0-11412]).

The non-coding regions of the human genome have been closely associated with the biological processes of disease ([@b6-ol-0-0-11412]). Furthermore, it has been demonstrated that lncRNAs, miRNAs and circRNAs all regulate the physiological and pathological processes of numerous types of cancer, and that these regulatory ncRNAs can affect the functions of their target mRNAs ([@b11-ol-0-0-11412],[@b17-ol-0-0-11412]--[@b19-ol-0-0-11412]). It has been reported that ncRNA molecules influence tumorigenesis and tumor progression by forming regulatory networks with their target genes ([@b10-ol-0-0-11412]), which corresponds with the multi-gene and multi-step regulation of tumor development.

Certain studies have investigated the ncRNA regulatory networks that influence the occurrence and development of various types of tumor, including NPC ([@b10-ol-0-0-11412],[@b11-ol-0-0-11412],[@b13-ol-0-0-11412],[@b20-ol-0-0-11412]). Therefore, in order to delineate an NPC-specific regulatory gene network containing ncRNAs in \>10,000 human genes, the comprehensive identification of NPC-associated DE ncRNAs and their targets represents the initial step in establishing this network. To the best of our knowledge, the present study is the first to simultaneously screen and predict the possible target genes of DE ncRNAs (lncRNAs, miRNAs and circRNAs) using three sets of high-throughput microarray data based on transcriptome profiling of NPC tissues. The results constitute a foundation for subsequent comprehensive studies into the regulatory network behind the molecular pathogenesis of NPC.

In the present study, \>100 DE lncRNAs and mRNAs were identified in NPC tissues. Subsequently, the NPC-associated nearby coding genes that may represent targets of DE lncRNAs were predicted via bioinformatics analysis, and their associations between DE lncRNAs, nearby coding genes and genome coordinates were also evaluated. Pathway analysis was conducted to determine the biological function of the selected DE mRNAs in NPC pathogenesis, and to predict the essential genes regulating various NPC-associated signaling pathways. Additional target genes of DE lncRNAs were identified from 31 significantly enriched signaling pathways associated with NPC. The results suggest that aberrantly expressed lncRNAs may influence NPC development and progression through certain mechanisms, such as the interaction between a DE lncRNA and its adjacent protein-coding gene, or via interaction with its target gene in the corresponding signaling pathway. Thus, lncRNA-mRNA networks may serve an important role in the transcriptional regulation of NPC.

Pathway analysis demonstrated that 31 signaling pathways were associated with DEGs, including 18 pathways associated with upregulated, and 13 associated with downregulated genes; three of these pathways ('cytokine-cytokine receptor interaction', 'chemokine signaling pathway' and 'neuroactive ligand-receptor interaction') were simultaneously associated with upregulated and downregulated signaling pathways. Of the 74 target genes associated with the above three pathways, 14 genes (LEP, CCL17, CCL19, CCL21, CXCL12, CCL2, CCL4, CCR8, CXCL10, CXCL2, CXCL3, CXCL6, CXCR6 and GHR) were separately involved in ≥2 of these pathways. The functions of these target genes were associated with the following biological processes: 'Signal transduction', 'cell adhesion and migration', 'cell proliferation', 'inflammatory cell infiltration', 'angiogenesis' and 'immunoregulation'. Additionally, various pathways and target genes were associated with the development and progression of several other human cancer types ([@b21-ol-0-0-11412]--[@b23-ol-0-0-11412]). The present results indicate that the three aforementioned pathways, and 14 identified genes, may represent key regulators of NPC tumorigenesis.

Additionally, multiple DE circRNAs associated with NPC, and their target miRNAs/mRNAs, were investigated alongside their corresponding association and genome mapping. However, thus far, no detailed reports are available on the association between circRNAs and their targets in NPC. The present study identified regulatory circRNA-miRNA-mRNA networks in NPC, which contained different modules consisting of relevant target genes. The current results indicate that aberrantly expressed circRNAs may influence different pathophysiological mechanisms of NPC via interaction with miRNAs and mRNAs, and also that the circRNA-miRNA-mRNA motifs serve a key regulatory function in NPC. Taken together, the present data indicate that lncRNAs do not serve an isolated role, but target the mRNAs of various other genes, and influence other associated genes involved in the tumorigenesis and progression of NPC, by forming regulatory networks.

In the circRNA-miRNA-mRNA network, 50 mRNAs were identified as the final functional genes. According to the National Center for Biotechnology Information gene database, the functions of these target genes were associated with the following physiological and pathological mechanisms: 'Environmental stress', 'cell motility and migration', 'cytoskeleton', 'antiproliferative activity', 'regulation of voltage-gated calcium channels', 'cell proliferation and apoptosis', 'desmosome formation', 'annexin', 'B lymphocyte antigen receptor' 'bimodal regulator of epidermal growth factor receptor and mitogen-activated protein kinase signaling', 'extracellular matrix protein' and 'chromosome segregation'. Notably, previous studies have revealed that certain identified target genes are associated with cancer cell proliferation and metastasis ([@b24-ol-0-0-11412],[@b25-ol-0-0-11412]), and thus serve important roles in NPC development and progression ([@b26-ol-0-0-11412]--[@b28-ol-0-0-11412]).

Overall, the present study simultaneously identified DE lncRNAs, circRNAs and mRNAs between NPC and CNP tissues via the integrated analysis of three transcriptome profiling datasets. Furthermore, potential target genes for these DE ncRNAs, and key signaling pathways associated with NPC, were identified using bioinformatics analysis. Finally, possible regulatory networks comprised of different modules in NPC were predicted and constructed. The present study serves to evaluate the association between these genes and NPC at the RNA transcriptome level. It also provides novel information to elucidate the molecular pathogenesis of NPC from a networking perspective. In further studies, the biological functions of these regulatory networks in NPC should be verified.
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Bioinformatics analysis of differentially expressed mRNAs in NPC and CNP tissues. (A) Volcano plot demonstrating the distribution of mRNAs. (B) Scatter plot exhibiting variation in mRNA expression. (C) Heatmap clustering indicating a distinguishable association between the mRNA expression patterns of certain samples. mRNA expression levels are indicated as follows; Red, high expression and green, low expression. NPC, nasopharyngeal carcinoma; CNP, chronic nasopharyngitis.
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Bioinformatics analysis of differentially expressed circRNAs in NPC and CNP tissues. (A) Volcano plot demonstrating the distribution of circRNAs. (B) Scatter plot exhibiting variation in circRNA expression. (C) Heatmap clustering indicating a distinguishable association between the circRNA expression patterns of certain samples. circRNAs expression levels are indicated as follows; Red, high expression and green, low expression. circRNA, circular RNA; NPC, nasopharyngeal carcinoma; CNP, chronic nasopharyngitis.
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Validation of selected (A) lncRNAs, (B) mRNAs and (C) circRNAs based on microarray and RT-qPCR data. Column heights represent the fold changes (log2 transformed) between NPC and CNP tissues, determined using RT-qPCR and microarray data. The validation results indicated a positive association between the RT-qPCR and microarray data. \*\*P\<0.01 vs. microarray. lncRNA, long non-coding RNA; circRNA, circular RNA; RT-qPCR, reverse transcription-quantitative PCR; NPC, nasopharyngeal carcinoma; CNP, chronic nasopharyngitis.
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![circRNA-miRNA-mRNA regulatory network in nasopharyngeal carcinoma. Green circle, miRNA; pink circle, circRNA; light-blue circle, mRNA. circRNA, circular RNA; miRNA, micro RNA.](ol-19-04-3123-g09){#f4-ol-0-0-11412}

![circRNA-miRNA-mRNA regulatory modules in nasopharyngeal carcinoma. Green rectangle, miRNA; pink rectangle, circRNA; light-blue rectangle, mRNA. circRNA, circular RNA; miRNA, micro RNA.](ol-19-04-3123-g10){#f5-ol-0-0-11412}
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Key signaling pathways associated with upregulated DEGs.

  Pathway ID   Definition                                                                      DEGs
  ------------ ------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------
  hsa04060     Cytokine-cytokine receptor interaction-*Homo sapiens* (human)                   CCL2, CCL4, CCR8, CXCL10, CXCL2, CXCL3, CXCL6, CXCR6, EGFR, FAS, GHR, IFNG, IL12A, IL15, IL22RA2, IL23A, LIFR, TNFRSF11B, TNFSF10, TNFSF18
  hsa05164     Influenza A-*Homo sapiens* (human)                                              CCL2, CXCL10, EIF2AK2, FAS, IFIH1, IFNG, IL12A, MX1, OAS1, OAS2, RSAD2, STAT1, TMPRSS13, TNFSF10
  hsa05162     Measles-*Homo sapiens* (human)                                                  EIF2AK2, FAS, IFIH1, IFNG, IL12A, MX1, OAS1, OAS2, STAT1, TNFSF10
  hsa00260     Glycine, serine and threonine metabolism-*Homo sapiens* (human)                 CHDH, GATM, PIPOX, PSAT1, SDS
  hsa04630     Jak-STAT signaling pathway-Homo sapiens (human)                                 GHR, IFNG, IL12A, IL13RA2, IL15, IL22RA2, IL23A, LIFR, SPRY2, STAT1
  hsa05160     Hepatitis C-*Homo sapiens* (human)                                              CLDN1, EGFR, EIF2AK2, IFIT1, OAS1, OAS2, PPP2R2B, PPP2R2C, STAT1
  hsa05168     Herpes simplex infection-*Homo sapiens* (human)                                 CCL2, EIF2AK2, FAS, IFIH1, IFIT1, IFNG, IL12A, IL15, OAS1, OAS2, STAT1
  hsa05142     Chagas disease (American trypanosomiasis)-*Homo sapiens* (human)                C1QB, CCL2, FAS, IFNG, IL12A, PPP2R2B, PPP2R2C
  hsa04940     Type I diabetes mellitus-*Homo sapiens* (human)                                 FAS, GAD1, IFNG, IL12A
  hsa05144     Malaria-*Homo sapiens* (human)                                                  CCL2, IFNG, IL12A, KLRK1
  hsa05412     Arrhythmogenic right ventricular cardiomyopathy (ARVC)-*Homo sapiens* (human)   CACNA2D1, DSG2, DSP, ITGAV, ITGB8
  hsa04062     Chemokine signaling pathway-*Homo sapiens* (human)                              CCL2, CCL4, CCR8, CXCL10, CXCL2, CXCL3, CXCL6, CXCR6, STAT1
  hsa04080     Neuroactive ligand-receptor interaction-*Homo sapiens* (human)                  C3AR1, CHRNA7, CHRNB4, EDN1, GABRE, GAL, GHR, GRIN2A, GZMA, LGR5, LHCGR, PPYR1, SSTR2
  hsa04066     HIF-1 signaling pathway-*Homo sapiens* (human)                                  ANGPT2, EDN1, EGFR, IFNG, NOX1, TF
  hsa05143     African trypanosomiasis-*Homo sapiens* (human)                                  FAS, IFNG, IL12A
  hsa05410     Hypertrophic cardiomyopathy (HCM)-*Homo sapiens* (human)                        CACNA2D1, EDN1, ITGAV, ITGB8, TPM1
  hsa04512     ECM-receptor interaction-*Homo sapiens* (human)                                 COL4A5, ITGAV, ITGB8, LAMA3, LAMB3
  hsa05132     Salmonella infection-*Homo sapiens* (human)                                     CCL4, CXCL2, CXCL3, DYNC1I1, IFNG

DEGs, differentially expressed genes.

###### 

Key signaling pathways associated with downregulated DEGs.

  Pathway ID   Definition                                                            DEGs
  ------------ --------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------
  hsa04640     Hematopoietic cell lineage-*Homo sapiens* (human)                     CD19, CD1C, CD22, CD37, CR1, CR2, FCER2, MME, MS4A1
  hsa04080     Neuroactive ligand-receptor interaction-*Homo sapiens* (human)        ADRA2A, CNR2, CTSG, EDN3, GALR2, GPR77, GRM5, HTR2A, LEP, MC1R, P2RX5, PRSS1, PRSS3, S1PR4, SCT, TAC4
  hsa04662     B cell receptor signaling pathway-*Homo sapiens* (human)              CD19, CD22, CD72, CD79A, CD79B, CR2, VAV3
  hsa05217     Basal cell carcinoma - *Homo sapiens* (human)                         GLI1, PTCH1, TCF7, WNT16, WNT9A
  hsa05340     Primary immunodeficiency-*Homo sapiens* (human)                       CD19, CD40LG, CD79A, TNFRSF13C
  hsa04340     Hedgehog signaling pathway-*Homo sapiens* (human)                     GLI1, PTCH1, WNT16, WNT9A
  hsa04064     NF-kappa B signaling pathway-*Homo sapiens* (human)                   CCL19, CCL21, CD40LG, CXCL12, TNFRSF13C
  hsa00920     Sulfur metabolism-*Homo sapiens* (human)                              SULT2B1, SUOX
  hsa04614     Renin-angiotensin system-*Homo sapiens* (human)                       CTSG, MME
  hsa04060     Cytokine-cytokine receptor interaction-*Homo sapiens* (human)         AMHR2, CCL17, CCL19, CCL21, CD40LG, CXCL12, LEP, TNFRSF10D, TNFRSF13C
  hsa04062     Chemokine signaling pathway-*Homo sapiens* (human)                    CCL17, CCL19, CCL21, CXCL12, GNG7, RASGRP2, VAV3
  hsa04672     Intestinal immune network for IgA production-*Homo sapiens* (human)   CD40LG, CXCL12, TNFRSF13C
  hsa05030     Cocaine addiction-*Homo sapiens* (human)                              CDK5R1, DLG4, FOSB

DEGs, differentially expressed genes.

###### 

Differentially expressed circRNAs and their miRNA binding sites.

  Differentially expressed circRNAs   miRNA binding sites                                                                                     
  ----------------------------------- --------------------- ------- ------------------ ----------------- ----------------- ------------------ -----------------
  hsa_circRNA_100160                  Up                    chr 1   hsa-miR-193b-5p    hsa-miR-518a-5p   hsa-miR-527       hsa-miR-1264       hsa-miR-584-3p
  hsa_circRNA_100181                  Up                    chr1    hsa-miR-223-5p     hsa-miR-148a-3p   hsa-miR-148b-3p   hsa-miR-152-3p     hsa-miR-146b-5p
  hsa_circRNA_100386                  Up                    chr1    hsa-miR-193a-5p    hsa-miR-149-3p    hsa-miR-1301-3p   hsa-miR-139-3p     hsa-miR-494-5p
  hsa_circRNA_100491                  Up                    chr1    hsa-miR-223-3p     hsa-miR-26a-5p    hsa-miR-26b-5p    hsa-miR-212-5p     hsa-miR-663a
  hsa_circRNA_100989                  Up                    chr11   hsa-miR-30b-3p     hsa-miR-889-5p    hsa-miR-766-3p    hsa-miR-509-3p     hsa-miR-608
  hsa_circRNA_101252                  Up                    chr13   hsa-miR-762        hsa-miR-654-3p    hsa-miR-1301-3p   hsa-miR-15a-3p     hsa-miR-145-5p
  hsa_circRNA_101728                  Up                    chr16   hsa-miR-518c-5p    hsa-miR-514a-5p   hsa-miR-762       hsa-miR-105-5p     hsa-miR-585-5p
  hsa_circRNA_101965                  Up                    chr17   hsa-miR-519d-5p    hsa-miR-489-3p    hsa-miR-376c-5p   hsa-miR-376b-5p    hsa-miR-298
  hsa_circRNA_102539                  Up                    chr19   hsa-miR-224-3p     hsa-miR-370-3p    hsa-miR-452-5p    hsa-miR-506-3p     hsa-miR-522-3p
  hsa_circRNA_102682                  Up                    chr2    hsa-miR-383-3p     hsa-miR-486-3p    hsa-miR-541-3p    hsa-miR-557        hsa-miR-18a-5p
  hsa_circRNA_102817                  Up                    chr2    hsa-miR-331-5p     hsa-miR-298       hsa-miR-296-3p    hsa-miR-30c-1-3p   hsa-miR-588
  hsa_circRNA_103578                  Up                    chr4    hsa-miR-149-5p     hsa-miR-650       hsa-miR-548a-3p   hsa-miR-148b-5p    hsa-miR-589-3p
  hsa_circRNA_103964                  Up                    chr5    hsa-miR-512-3p     hsa-miR-215-3p    hsa-miR-492       hsa-miR-105-5p     hsa-miR-200a-3p
  hsa_circRNA_103965                  Up                    chr5    hsa-miR-512-3p     hsa-miR-215-3p    hsa-miR-492       hsa-miR-105-5p     hsa-miR-377-3p
  hsa_circRNA_104204                  Up                    chr6    hsa-miR-619-5p     hsa-miR-370-3p    hsa-miR-448       hsa-miR-18b-5p     hsa-miR-18a-5p
  hsa_circRNA_104244                  Up                    chr6    hsa-miR-892b       hsa-miR-149-5p    hsa-miR-130b-5p   hsa-miR-1271-3p    hsa-miR-432-3p
  hsa_circRNA_104405                  Up                    chr7    hsa-miR-122-5p     hsa-miR-205-5p    hsa-miR-136-5p    hsa-miR-214-3p     hsa-miR-138-5p
  hsa_circRNA_104589                  Up                    chr8    hsa-miR-511-5p     hsa-miR-548d-5p   hsa-miR-548b-5p   hsa-miR-548c-5p    hsa-miR-658
  hsa_circRNA_000250                  Down                  chr18   hsa-miR-181c-5p    hsa-miR-181b-5p   hsa-miR-181d-5p   hsa-miR-224-3p     hsa-miR-181a-5p
  hsa_circRNA_000526                  Down                  chr10   hsa-miR-92a-2-5p   hsa-miR-488-5p    hsa-miR-542-3p    hsa-miR-525-5p     hsa-miR-193b-5p
  hsa_circRNA_001430                  Down                  chr5    hsa-miR-92a-2-5p   hsa-miR-491-5p    hsa-miR-16-5p     hsa-let-7g-5p      hsa-miR-193a-5p
  hsa_circRNA_100044                  Down                  chr1    hsa-miR-629-3p     hsa-miR-486-3p    hsa-miR-134-3p    hsa-miR-877-3p     hsa-miR-377-5p
  hsa_circRNA_100499                  Down                  chr1    hsa-miR-504-3p     hsa-miR-21-5p     hsa-miR-337-3p    hsa-miR-642a-5p    hsa-miR-16-2-3p
  hsa_circRNA_101969                  Down                  chr17   hsa-miR-18a-3p     hsa-miR-519a-5p   hsa-miR-519b-5p   hsa-miR-519c-5p    hsa-miR-518e-5p
  hsa_circRNA_102062                  Down                  chr17   hsa-miR-18a-5p     hsa-miR-485-5p    hsa-miR-150-3p    hsa-miR-433-5p     hsa-miR-18b-5p
  hsa_circRNA_102113                  Down                  chr17   hsa-miR-106b-3p    hsa-miR-545-5p    hsa-miR-766-5p    hsa-miR-660-3p     hsa-miR-625-5p
  hsa_circRNA_102224                  Down                  chr17   hsa-miR-17-3p      hsa-miR-520g-3p   hsa-miR-422a      hsa-miR-520h       hsa-miR-545-3p
  hsa_circRNA_102226                  Down                  chr17   hsa-miR-17-3p      hsa-miR-802       hsa-miR-495-3p    hsa-miR-143-5p     hsa-miR-516b-5p
  hsa_circRNA_102535                  Down                  chr19   hsa-miR-221-5p     hsa-miR-431-5p    hsa-miR-602       hsa-miR-662        hsa-miR-661
  hsa_circRNA_103992                  Down                  chr5    hsa-miR-1301-3p    hsa-miR-130b-5p   hsa-miR-204-3p    hsa-miR-29b-1-5p   hsa-miR-877-3p
  hsa_circRNA_104652                  Down                  chr8    hsa-miR-25-3p      hsa-miR-512-3p    hsa-miR-134-5p    hsa-miR-134-3p     hsa-let-7i-5p

circRNA, circular RNA; miRNA, micro RNA; MRE, miRNA recognition elements.

###### 

Nearby coding genes for long intergenic non-coding RNAs.

  Sequence name     Gene symbol      Genomic location              GR   Nearby gene
  ----------------- ---------------- ----------------------------- ---- -----------------
  AW833912                           Chr 3: 172556888-172557496    D    NM_018098
  BF108976                           Chr 2: 192068946-192069452    D    NM_007315
  BG953017R                          Chr 4: 184736396-184736595    U    ENST00000296741
  ENST00000400353   AP000569.8       Chr 21: 35303517-35343487     U    NM_001001132
  ENST00000411844   KIAA0664L3       Chr 16: 3171560031717339      U    ENST00000389202
  ENST00000412797   RP11-70P17.1     Chr 1: 25907968-25916847      D    NM_024037
  ENST00000413991   AC073257.2       Chr 2: 121300484-121301902    U    NM_005270
  ENST00000420672   AC009948.5       Chr 2: 179278665-179295551    U    NM_145739
  ENST00000425214   CCDC144B         Chr 17: 18494172-18507053     U    NM_016078
  ENST00000431729   RP11-191N8.2     Chr 1: 222001007-222014008    D    NM_144729
  ENST00000434893   GUSBP11          Chr 22: 23995356-24029101     U    NM_013378
  ENST00000438082   RP11-57C13.6     Chr 10: 89367741-89419036     D    NM_004670
  ENST00000439051   RP11-57C13.6     Chr 10: 89367768-89419036     D    NM_004670
  ENST00000439472   TTTY10           Chr Y: 22669139-22680293      U    NM_001039567
  ENST00000440357   RP4-738P15.1     Chr 20: 25124000-25129876     D    ENST00000480798
  ENST00000441287   AC011193.1       Chr 17: 32806352-32806976     U    NM_002982
  ENST00000442583   CCDC144B         Chr 17: 18491592-18509704     U    NM_016078
  ENST00000449023   SRGAP3-AS4       Chr 3: 9298442-9299191        U    NM_014850
  ENST00000457217   RP11-222A5.1     Chr 1: 175846478-175849604    U    NM_003285
  ENST00000483245   RP11-202A13.1    Chr 3: 133774099-133776492    D    NM_001063
  ENST00000486295   EGFEM1P          Chr 3: 168538977-168547319    D    ENST00000264674
  ENST00000514571   CTC-454M9.1      Chr 5: 88261691-88464485      U    NM_001193347
  ENST00000520323   CTB-11I22.2      Chr 5: 158654722-158672135    U    NM_024007
  ENST00000520840   RP11-875O11.3    Chr 8: 22928889-22932001      U    ENST00000312584
  ENST00000536112   RP11-81H14.2     Chr 12: 68825634-68826434     D    NM_000619
  ENST00000537192   RP11-1038A11.3   Chr 12: 5399645-5487520       D    NM_002527
  ENST00000538430   RP11-1038A11.1   Chr 12: 5497754-5515817       D    NM_002527
  ENST00000539404   RP11-81H14.2     Chr 12: 68726727-68797580     D    NM_000619
  ENST00000541707   RP11-81H14.2     Chr 12: 68726667-68729561     D    NM_000619
  ENST00000544591   RP11-291B21.2    Chr 12: 10705961-10710648     U    NM_007333
  ENST00000544842   RP11-319E16.2    Chr 12: 5425126-5428513       D    NM_002527
  ENST00000546086   RP11-81H14.2     Chr 12: 68727032-68835996     D    NM_000619
  ENST00000546968   RP11-44N21.1     Chr 14: 105561527-105565341   U    NM_138790
  ENST00000548846   RP3-473L9.4      Chr 12: 111834638-111841111   D    NM_001136538
  ENST00000549710   RP11-498M15.1    Chr 12: 72102950-72104154     D    NM_003667
  ENST00000552154   RP11-554D14.7    Chr 12: 108226634-108228807   D    ENST00000342331
  ENST00000556624   RP11-219E7.1     Chr 14: 21252046-21252452     D    ENST00000298687
  ENST00000558147   LINC00277        Chr 15; 69373189-69383734     U    ENST00000310673
  ENST00000558419   CTD-2008A1.1     Chr 15: 45118737-45119292     D    NM_003104
  ENST00000559914   LINC00277        Chr 15: 69365277-69367206     U    ENST00000310673
  ENST00000561384   CTD-2008A1.2     Chr 15: 45119397-45176892     U    NM_003104
  ENST00000562834   RP3-523K23.2     Chr 6: 54807964-54809897      U    NM_001010872
  ENST00000563852   RP11-506G7.1     Chr 17: 41020507-41025481     D    NM_007299
  ENST00000564832   RP11-531A24.3    Chr 8: 73859384-73862680      D    NM_001243237
  ENST00000566575   CTA-250D10.23    Chr 22: 42318026-42319104     D    NM_001207020
  ENST00000568337   RP11-160C18.2    Chr 15: 79021382-79026298     U    NM_000750
  ENST00000569215   RP11-609N14.1    Chr 16: 10445296-10446609     D    NM_001134407
  ENST00000569655   RP11-143K11.1    Chr 17: 71171621-71172772     U    NM_001050
  ENST00000569892   RP11-114H24.3    Chr 15: 78246416-78255996     U    NM_015162
  ENST00000575693   LA16c-325D7.2    Chr 16: 2916348-2917619       U    NM_024507
  ENST00000577807   RP11-599B13.3    Chr 17: 7959542-7960939       D    NM_001039131
  HMlincRNA791−     HMlincRNA791     Chr 18: 52298998-52308760     U    NM_001143829
  HMlincRNA963+     HMlincRNA963     Chr 3: 168554930-168560248    D    ENST00000264674
  NR_024475         LOC100216001     Chr 10: 4692376-4720262       U    NM_001353
  NR_026878         FOXD2-AS1        Chr 1: 47897806-47900313      D    ENST00000337817
  NR_027994         NHEG1            Chr 6: 137303295-137314368    U    NM_181310
  NR_038293         LOC100507173     Chr 6: 27661813-27678001      D    ENST00000331442
  NR_040109         LOC100505495     Chr 19: 41960073-42006554     U    NM_006890
  TCONS_00001315    XLOC_000595      Chr 1: 227976987-227979782    D    NM_003395
  TCONS_00001451    XLOC_000781      Chr 1: 35081179-35083207      U    NM_005268
  TCONS_00005258    XLOC_002368      Chr 2: 160780449-160792478    U    NM_001007267
  TCONS_00005268    XLOC_002383      Chr 2: 169197716-169198115    U    NM_203463
  TCONS_00006514    XLOC_003131      Chr 3: 54048256-54065456      D    NM_018397
  TCONS_00008529    XLOC_004016      Chr 4: 90459366-90472707      U    ENST00000420646
  TCONS_00009933    XLOC_004361      Chr 5: 42922835-42924839      U    NM_000163
  TCONS_00010742    XLOC_004475      Chr 5: 92906525-92909378      D    NM_005654
  TCONS_00011633    XLOC_005123      Chr 6: 1489677-1490173        U    NM_033260
  TCONS_00011758    XLOC_005220      Chr 6: 27677988-27680876      D    ENST00000331442
  TCONS_00012442    XLOC_005214      Chr 6: 26674955-26677930      U    NM_001732
  TCONS_00012443    XLOC_005214      Chr 6: 26675224-26688063      U    NM_001732
  TCONS_00014617    XLOC_006712      Chr 8: 11500332-11506826      U    NM_001715
  TCONS_00014681    XLOC_006779      Chr 8: 39891375-39891902      U    NM_001464
  TCONS_00017282    XLOC_008100      Chr X: 2484083-2488088        U    NM_001141919
  TCONS_00017293    XLOC_008116      Chr X: 13405670-13437996      U    NM_001167890
  TCONS_00018417    XLOC_008704      Chr 10: 4790106-4806336       U    NM_001353
  TCONS_00021032    XLOC_009637      Chr 12: 7491433-7494514       U    NM_031491
  TCONS_00021064    XLOC_009662      Chr 12: 10725616-10727581     U    NM_007333
  TCONS_00029036    XLOC_013955      Chr 21: 44232379-44237997     U    NM_001001568
  TCONS_00029753    XLOC_014147      Chr 22: 18848963-18851914     U    NM_017414
  TCONS_00029855    XLOC_014297      Chr 22: 19543858-19552723     D    NM_001178010
  uc001yfd.1        BX247990         Chr 14: 96181819-96223116     D    NM_001252507
  uc002ebp.1        TRIM72           Chr 16: 31237192-31237830     D    ENST00000389202
  uc002iby.2        LOC388387        Chr 17: 41026690-41050751     D    NM_001158
  uc002nbr.3        UCA1             Chr 19: 15939756-15946230     D    ENST00000344824
  uc002zbk.2        BC041455         Chr 21: 44019513-44035168     U    NM_001001568
  .uc002zob.1       GGT3P            Chr 22: 18761201-18792992     D    NM_017414
  uc003fif.1        AK127557         Chr 3: 172308502-172312373    D    ENST00000241261
  uc003ihb.3        BC042378         Chr 4: 134114523-134115760    U    ENST00000264360
  uc003qhh.4        NHEG1            Chr 6: 137303295-137314368    U    NM_181310
  uc010jbc.2        FLJ42709         Chr 5: 92877577-92916738      U    NM_005654
  uc010vdm.1        RRN3P2           Chr 16: 29086162-29107582     U    NM_001178098

Chr, chromosome; GR, genome relationship; U, upstream; D, downstream.

###### 

Nearby coding genes for enhancer long non-coding RNAs.

  Sequence name     Gene symbol    Genomic location             GR   Nearby gene
  ----------------- -------------- ---------------------------- ---- -----------------
  ENST00000400353   AP000569.8     Chr 21: 35303517-35343487    U    NM_001001132
  ENST00000411844   KIAA0664L3     Chr 16: 31715600-31717339    U    ENST00000389202
  ENST00000412797   RP11-70P17.1   Chr 1: 25907968-25916847     D    NM_024037
  ENST00000431729   RP11-191N8.2   Chr 1: 222001007-222014008   D    NM_144729
  ENST00000440357   RP4-738P15.1   Chr 20: 25124000-25129876    D    ENST00000480798
  ENST00000440357   RP4-738P15.1   Chr 20: 25124000-25129876    U    NM_021067
  ENST00000441287   AC011193.1     Chr 17: 32806352-32806976    U    NM_002982
  NR_024475         LOC100216001   Chr 10: 4692376-4720262      U    NM_001353
  NR_026878         FOXD2-AS1      Chr 1: 47897806-47900313     D    ENST00000337817
  NR_027994         NHEG1          Chr 6: 137303295-137314368   U    NM_181310
  uc003qhh.4        NHEG1          Chr 6: 137303295-137314368   U    NM_181310

Chr, chromosome; GR, genome relationship; U, upstream; D, downstream.

###### 

Regulatory network components of differentially expressed circRNAs in nasopharyngeal carcinoma.

  circRNA identifier   Regulation   miRNA             mRNA
  -------------------- ------------ ----------------- ---------------------------------
  hsa_circRNA_100181   Up           hsa-miR-148a-3p   GADD45A, ROBO1
                                    hsa-miR-148b-3p   GADD45A, ROBO1
                                    hsa-miR-152-3p    GADD45A, ROBO1, WDR47
  hsa_circRNA_104405   Up           hsa-miR-122-5p    RIMS1
                                    hsa-miR-205-5p    CENPF, FRK, SCD5
                                    hsa-miR-214-3p    GALNTL4
  hsa_circRNA_102682   Up           hsa-miR-486-3p    SNCA
                                    hsa-miR-18a-5p    BTG3
  hsa_circRNA_102539   Up           hsa-miR-506-3p    DLX5, E2F5, FOXQ1, FRAS1, PARP9
                                    hsa-miR-522-3p    F5, TBCE
  hsa_circRNA_103578   Up           hsa-miR-149-5p    FAM18B2
                                    hsa-miR-650       ANXA4
  hsa_circRNA_101252   Up           hsa-miR-145-5p    ITGB8, MPZL1
  hsa_circRNA_101965   Up           hsa-miR-489-3p    PKP1
                                    hsa-miR-298       SAMD9
  hsa_circRNA_103965   Up           hsa-miR-377-3p    IRX3, PCDH10
  hsa_circRNA_104204   Up           hsa-miR-448       BTG3, NTF3, SPRY2, TBX3
                                    hsa-miR-18b-5p    BTG3
                                    hsa-miR-18a-5p    BTG3
  hsa_circRNA_102817   Up           hsa-miR-298       SAMD9
                                    hsa-miR-588       RIMS1
  hsa_circRNA_104244   Up           hsa-miR-149-5p    FAM18B2
  hsa_circRNA_103964   Up           hsa-miR-200a-3p   GATA6, MPPED2, RIMS1
  hsa_circRNA_100989   Up           hsa-miR-509-3p    C1orf172
                                    hsa-miR-608       FXYD7
  hsa_circRNA_100160   Up           hsa-miR-518a-5p   JAKMIP1, RAPGEF5
  hsa_circRNA_100491   Up           hsa-miR-223-3p    GALNTL4, RCN2
                                    hsa-miR-26a-5p    NFE2L3, RCN2
                                    hsa-miR-26b-5p    NFE2L3, RCN2
  hsa_circRNA_104589   Up           hsa-miR-548d-5p   BTG3, NTF3
                                    hsa-miR-548b-5p   BTG3, NTF3
                                    hsa-miR-548c-5p   BTG3, NTF3
  hsa_circRNA_100044   Down         hsa-miR-486-3p    DMKN, NR2F1
  hsa_circRNA_104652   Down         hsa-miR-25-3p     ADAMTSL1, KLF2, PPP1R12C
  hsa_circRNA_000526   Down         hsa-miR-542-3p    KLHL14
                                    hsa-miR-525-5p    ALPL, DCHS1, PFKFB2
  hsa_circRNA_001430   Down         hsa-miR-16-5p     C18orf34, SH3GL2
  hsa_circRNA_102062   Down         hsa-miR-485-5p    CD79A
  hsa_circRNA_102224   Down         hsa-miR-422a      ADD2
  hsa_circRNA_102226   Down         hsa-miR-802       MSI1
                                    hsa-miR-516b-5p   ALPL

circRNA, circular RNA; miRNA/miR, micro RNA.
